---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-023584"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2022-05-03T23:59:59+00:00"
generated_at: "2026-06-26T01:36:00.707728+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q1 net loss $4.1M; cash $65.2M, RADR platform tops 20B data points

## Summary
- Cash and marketable securities $65.2M at March 31, 2022 vs $70.7M at Dec 31, 2021; net cash used $5.3M in Q1.
- Net loss $4.1M ($0.38/share) vs $2.5M ($0.24) in Q1 2021; R&D expenses rose to $2.7M from $1.3M.
- RADR AI platform surpassed 20 billion data points; on track for 25 billion by year-end 2022.
- IND for LP-184 targeted for Q3 2022; HARMONIC Phase 2 trial for LP-300 expected to start enrollment summer 2022.
- Share repurchase program extended; $3.6M remaining authorized through July 31, 2022.

## SEC filing metadata
- accession: 0001213900-22-023584
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2022-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000121390022023584/0001213900-22-023584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000121390022023584/ea159290-8k_lantern.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-023584
- JSON: https://secwatch.observer/filing/0001213900-22-023584.json
- Plain text: https://secwatch.observer/filing/0001213900-22-023584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.